Key facts
- This page summarizes Flagship Ventures Fund V General Partner LLC's Form 4 filing for Sana Biotechnology, Inc. (SANA).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jun 2023, 19:00.
Flagship Ventures Fund V General Partner LLC - 06 Jun 2023 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- SANA
- Reported as of
- 06 Jun 2023
- Net transaction value
- -$2,532,858
- SEC form
- 4
- Accepted by SEC
- 08 Jun 2023, 19:00:14 UTC
- Prior SEC filing
- 26 May 2023
- Next SEC filing
- 15 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- Flagship Ventures Fund V General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Manager
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Flagship Ventures Fund V General Partner LLC filed Form 4 for Sana Biotechnology, Inc. (SANA) on 08 Jun 2023.
Change
- Previous filing in this sequence was filed on 26 May 2023.
- Current net transaction value: -$2,532,858.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SANA
transaction
Common Stock
Sale
- Transaction value
- $1,144,311
- Shares
- -181,461
- Change %
- -1.6%
- Price
- $6.31
- Shares after
- 10,920,533
- Date
- 06 Jun 2023
- Ownership
- By Flagship Ventures Fund V, L.P.
- Footnotes
- F1, F2
SANA
transaction
Common Stock
Sale
- Transaction value
- $140,607
- Shares
- -22,297
- Change %
- -1.6%
- Price
- $6.31
- Shares after
- 1,403,037
- Date
- 06 Jun 2023
- Ownership
- By Flagship V VentureLabs Rx Fund, L.P.
- Footnotes
- F1, F3
SANA
transaction
Common Stock
Sale
- Transaction value
- $1,105,924
- Shares
- -177,240
- Change %
- -1.6%
- Price
- $6.24
- Shares after
- 10,743,293
- Date
- 07 Jun 2023
- Ownership
- By Flagship Ventures Fund V, L.P.
- Footnotes
- F2, F4
SANA
transaction
Common Stock
Sale
- Transaction value
- $142,016
- Shares
- -22,760
- Change %
- -1.6%
- Price
- $6.24
- Shares after
- 1,380,277
- Date
- 07 Jun 2023
- Ownership
- By Flagship V VentureLabs Rx Fund, L.P.
- Footnotes
- F3, F4
SANA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,441,326
- Date
- 06 Jun 2023
- Ownership
- By Flagship VentureLabs V, LLC
- Footnotes
- F5
SANA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 9,725,122
- Date
- 06 Jun 2023
- Ownership
- By Flagship Pioneering Fund VI, L.P.
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.415, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F2
Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F3
Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.36, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F5
Represents shares held directly by Flagship VentureLabs V LLC. ("VentureLabs V"). VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F6
Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.